[EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS BENZÈNESULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
申请人:XENON PHARMACEUTICALS INC
公开号:WO2017201468A1
公开(公告)日:2017-11-23
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
[EN] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS INDOLIQUES UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES
申请人:NIDO BIOSCIENCES INC
公开号:WO2022020342A1
公开(公告)日:2022-01-27
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof.
Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
Oxalates as Activating Groups for Alcohols in Visible Light Photoredox Catalysis: Formation of Quaternary Centers by Redox-Neutral Fragment Coupling
作者:Christopher C. Nawrat、Christopher R. Jamison、Yuriy Slutskyy、David W. C. MacMillan、Larry E. Overman
DOI:10.1021/jacs.5b07678
日期:2015.9.9
Alkyl oxalates are new bench-stable alcohol-activating groups for radical generation under visiblelightphotoredox conditions. Using these precursors, the first net redox-neutralcoupling of tertiary and secondary alcohols with electron-deficient alkenes is achieved.
[EN] BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS<br/>[FR] BENZOFUROPYRIMIDINONES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
申请人:EXELIXIS INC
公开号:WO2009086264A1
公开(公告)日:2009-07-09
A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.